Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1726 to 1740 of 8971 results

  1. Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TSID10722]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Dupilumab for children with severe atopic dermatitis [TSID10434]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. CT-P43 (ustekinumab biosimilar) for treating moderate to severe plaque psoriasis [TSID11773]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Dulaglutide for treating type 2 diabetes in children and young people [TSID10660]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [TSID12043]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Linaclotide acetate for treating Chronic idiopathic constipation [TSID12005]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Eszopiclone for treating insomnia [TSID12020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. IgPro20 for treating dermatomyositis [TSID12014]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin [TSID11940]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Olorofim for treating invasive fungal infections in people 16 years and over [TSID11983]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years [TSID12002]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Secukinumab biosimilar for treating plaque psoriasis [TSID11992]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [TSID11969]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation